Showing results (1-10 of 31) with videos related to
Sort By:
Pageof 4
Vaccine|January 30, 2013
Association of infant pneumococcal vaccination with pneumococcal pneumonia among mothers: a nested case-control study using the GPRDEelko Hak, Kimberly M Shea, Susan S JickInfectious Disease Clinics of North America|November 28, 2015
Pneumococcal Disease in the Era of Pneumococcal Conjugate VaccineInci Yildirim, Kimberly M Shea, Stephen I PeltonTrials|March 30, 2013
Randomized clinical trials to identify optimal antibiotic treatment durationC Robert Horsburgh, Kimberly M Shea, Patrick Phillips, et al.Plos One|October 14, 2017
Risk of exacerbation following pneumonia in adults with heart failure or chronic obstructive pulmonary diseaseRebecca Bornheimer, Kimberly M Shea, Reiko Sato, et al.Journal of Asthma and Allergy|May 23, 2019
Pneumonia in young adults with asthma: impact on subsequent asthma exacerbationsStephen I Pelton, Kimberly M Shea, Rebecca Bornheimer, et al.The Pediatric Infectious Disease Journal|December 18, 2010
Underlying conditions in children with invasive pneumococcal disease in the conjugate vaccine eraKatherine K Hsu, Kimberly M Shea, Abbie E Stevenson, et al.The Pediatric Infectious Disease Journal|November 26, 2009
Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007Katherine K Hsu, Kimberly M Shea, Abbie E Stevenson, et al.BMC Public Health|May 16, 2008
Implications for registry-based vaccine effectiveness studies from an evaluation of an immunization registry: a cross-sectional studyBarbara E Mahon, Kimberly M Shea, Nancy N Dougherty, et al.Vaccine|November 22, 2023
Maternal Tdap and influenza vaccination uptake 2017-2021 in the United States: Implications for maternal RSV vaccine uptake in the futureAmy W Law, Jennifer Judy, Jessica E Atwell, et al.Vaccine|May 18, 2025
Cost-effectiveness of bivalent respiratory syncytial virus Prefusion F (RSVpreF) maternal vaccine among infants in the United StatesAhuva Averin, Erin Quinn, Mark Atwood, et al.Pageof 4